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Summary 
AIMS OF THE STUDY: The aim of this study was to iden-
tify possible risk factors for the development of leucope-
nia associated with metamizole use. 
METHODS: A retrospective case-control study was per-
formed. Cases of metamizole-associated leucopenia 
managed at a single centre (2005–2013) were character-
ised and compared with matched controls who took 
metamizole without developing complications. 
RESULTS: Fifty-seven cases and 139 controls were iden-
tified. Of the cases, 32 were postoperative and these 
were compared to age-, sex- and ward-matched postop-
erative controls (n = 64). The remaining cases (n = 25) 
were compared to sex-matched, non-postoperative 
controls (n = 75). The number of patients with a positive 
allergy history was higher among postoperative cases 
than controls (p = 0.004) as was the number with previ-
ous leucopenic episodes (p = 0.03). The prevalence of di-
agnosed hepatitis C infection was 9% among all cases 
compared with 1% among all controls (p = 0.005). The 
use of concomitant cytostatic agents (even at immuno-
suppressive doses) was significantly higher among non-
postoperative cases than controls (p = 0.011). There was 
no association between renal function and the develop-
ment of leucopenia. 
CONCLUSIONS: A history of allergies, previous leucope-
nic episodes, hepatitis C infection and concomitant cy-
tostatic agents are possible risk factors for leucopenia 
associated with metamizole use. 
Key words: metamizole; dipyrone; leucopenia; agranu-
locytosis; adverse drug reaction 
Introduction 
Metamizole (dipyrone) is an old antipyretic and an-
algesic drug whose mechanism of action is not com-
pletely known, but postulated by some investigators 
to be similar to that of nonsteroidal anti-inflamma-
tory drugs [1]. Metamizole was first licensed in 
Switzerland in 1949 [2]. Its safety profile – in par-
ticular the risk of blood disorders including agranu-
locytosis – is controversial. This has led many coun-
tries to withdraw or withhold metamizole from the 
market. Australia withdrew metamizole in 1964, 
USA in 1977, Singapore in 1978 and Sweden in 
1974 [3, 4]. Sweden reintroduced metamizole in 
1995, only to withdraw it again in 1999 on account 
of agranulocytosis cases [4]. However, in other 
countries such as Switzerland and Germany, met-
amizole is still frequently used and has even gained 
market share in recent years [5, 6], most likely be-
cause of its good overall clinical efficacy and toler-
ability. Routine monitoring of blood counts while 
under metamizole therapy is not common practice 
and is not included in the drug label. The drug label, 
however, clearly states that patients should be made 
aware of this adverse drug reaction and that they 
should seek medical attention if they develop fever, 
cold symptoms, mucositis or sore throat [7]. The 
mechanism by which metamizole causes blood dis-
orders has not yet been fully elucidated. Available 
data suggest an immunological process, as well as 
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direct toxicity towards the progenitor cells in the 
bone marrow [8]. 
In the 1980s, a large population-based case-control 
study examined the risk of agranulocytosis or aplas-
tic anaemia during treatment with several drugs, in-
cluding metamizole [9]. The study found that the in-
cidence of metamizole-induced agranulocytosis 
varied markedly between countries. Little is known, 
however, about the underlying risk factors for de-
veloping blood cell disorders under metamizole. If 
strong risk factors are found, these could be used to 
identify patients for whom metamizole should be 
avoided. Conversely, patients who do not possess 
identified risk factors may benefit from the ad-
vantages of metamizole over other analgesics such 
as paracetamol and nonsteroidal anti-inflammatory 
drugs. Metamizole would therefore be applied in a 
safer, more targeted fashion. 
A number of studies have characterised cases of 
metamizole-induced white blood cell disorders [4–
6]; however as far as we know, no case-control stud-
ies have been performed. In the recently published 
study by Huber and colleagues, data from a prospec-
tive case-control surveillance study were used, but 
the presented results only contain data pertaining to 
the cases [6]. 
The aim of the present study was, therefore, to com-
pare cases of metamizole-associated leucopenia 
with control patients to identify possible risk factors 
for developing this complication and thus to im-
prove our knowledge about the risk-benefit profile 
of metamizole. 
Methods 
This retrospective, descriptive case-control study 
examined cases of metamizole-associated leucope-
nia that were managed at the University Hospital in 
Basel, Switzerland, between April 2005 and August 
2013. Cases were either postoperative or non-post-
operative. In order to avoid confounding by selec-
tion, cases were compared with postoperative and 
non-postoperative controls. Postoperative cases 
were compared with age-, sex-, and ward-matched 
postoperative control patients who had received 
metamizole without complication between 2005 
and 2013. Non-postoperative cases were compared 
with sex-matched control patients who had received 
metamizole for at least 4 weeks between 2001 and 
2014 in primary care settings in the Basel area with-
out complication. The study was approved by the 
local ethics committee “Ethikkommission Beider 
Basel” (protocol number EKBB 2013/130). As data 
were analysed anonymously, no patient informed 
consent was required. 
Selection and assessment of cases 
The electronic medical records of the University 
Hospital Basel were screened for the keywords 
“metamizole” or “Novalgin” in combination with 
“agranulocytosis”, “neutropenia” or “leucopenia”. 
Additionally, the in-patient referrals to the haema-
tology department which included the keyword 
“Novalgin” were screened for metamizole-associ-
ated leucopenia. Cases of leucopenia (leucocyte 
count below 3.5 × 109/l) occurring during met-
amizole exposure and prompting the discontinua-
tion of metamizole were included. The definition of 
leucopenia, a leucocyte count below 3.5 × 109/l, was 
in accordance with the local population reference 
range set by the diagnostic haematology laboratory, 
University Hospital Basel. All procedures were per-
formed according to the standard operating proce-
dure of our accredited laboratories (ISO/IEC 17025 
and ISO 15189). 
We evaluated demographic data such as age at the 
time of diagnosis of the adverse drug reaction 
(ADR) and body mass index (BMI), underlying dis-
eases, history of immediate- and delayed-type hy-
persensitivity reactions (“allergy”), comedication, 
drug administration information (dose, route, fre-
quency) as well as duration of metamizole therapy, 
latency time of the ADR, laboratory findings and 
the outcome and treatment of the ADR for each 
case. Comedication with drugs known to be associ-
ated with acute agranulocytosis (level 1 evidence 
according to Andersohn and colleagues) were taken 
into consideration when assessing ADR causality 
[10] and were named “potentially myelotoxic”. The 
concomitant use of cytostatic agents (which cause 
dose-dependent myelotoxicity) such as cancer 
chemotherapeutic drugs or immunosuppressant-
dose methotrexate (maximum 30 mg/week oral or 
subcutaneous) or azathioprine (maximum 5 mg/kg 
body weight / day) was also recorded. We assessed 
ADR causality according to the Naranjo ADR prob-
ability scale, which includes assessment of other 
possible causes such as comorbidities and comedi-
cation [11]. Only cases with an at least “possible” 
causality assessment according the Naranjo scale 
were evaluated further. 
Using the available dosage information, therapy and 
ADR dates, we calculated the daily dose, cumula-
tive dose, duration of treatment, latency time and 
duration of the ADR. The latency time was calcu-
lated as the period between the metamizole start 
date and the date of ADR onset according to labor-
atory assessments as defined above. If metamizole 
was prescribed as an “as required” medication and 
metamizole intake and dosage regimen were not 
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known with confidence, the daily dose was deter-
mined as the mean of the minimal daily dose (500 
mg) and the individual’s maximal prescribed daily 
dose (14 of 57 cases). 
Full blood counts (haemoglobin, leucocyte and 
platelet counts) were recorded at the start date of the 
metamizole therapy, during metamizole therapy 
(controls) or when the leucocyte count reached its 
nadir (cases). Since metabolites of metamizole are 
mainly renally excreted and their accumulation in 
renal impairment might be a risk factor for the de-
velopment of leucopenia, glomerular filtration rate 
(GFR) was estimated (Chronic Kidney Disease Ep-
idemiology Collaboration [CKD-EPI] formula [12]) 
at the start of metamizole therapy and at the start of 
the ADR (cases) or before and during metamizole 
therapy (controls). 
Selection and assessment of controls 
Postoperative controls 
The electronic medical records of the University 
Hospital Basel were screened for postoperative pa-
tients treated between 2005 and 2013 who received 
metamizole as postoperative analgesia and were dis-
charged with a prescription for daily metamizole 
until resolution of pain. A discharge prescription for 
metamizole was taken to indicate good clinical drug 
tolerability (as confirmed by the absence of fever, 
sore throat, cold symptoms or mucositis). Specifi-
cally, these patients were not known to develop any 
haematological complications. Two age- (±5 years), 
sex-, and ward-matched controls per postoperative 
case were randomly chosen from the list of all pos-
sible controls (n = 21 381) by use of a list random-
iser provided by random.org [13]. We evaluated de-
mographic data (sex, age at last intake, BMI), un-
derlying diseases, history of allergy, comedication, 
and if available, laboratory findings (full blood 
count and GFR) before and during metamizole ther-
apy. Comedication was evaluated in the same man-
ner as for the cases. Cumulative metamizole dose 
and duration of treatment were not known because 
these patients were discharged home with a met-
amizole prescription. 
Non-postoperative controls 
Non-postoperative controls were selected from an 
outpatient setting to ensure selection of patients who 
had been regularly exposed to metamizole for at 
least 4 weeks without developing haematological 
complications. The minimum duration of met-
amizole intake in this non-postoperative control 
group was chosen according to the latency time data 
from our previous pharmacovigilance study [5]. In 
that study, 84% of the cases occurred within 28 days 
of metamizole treatment. General practitioners in 
the Basel area were asked to identify patients who 
had taken metamizole continuously for at least 28 
days at a dosage of at least 500 mg per day and who 
had not developed any obvious blood disorders. As 
a result of the rarity of such controls, it was only 
possible to sex-match them with the cases. Data 
were collected from the medical records. 
Using the available dosage information and therapy 
dates, we calculated the daily dose, cumulative dose 
and duration of treatment of the corresponding epi-
sode of metamizole intake. If metamizole was pre-
scribed as an “as required” medication, and met-
amizole intake and dosage regimen were not known 
with confidence, the same method as described 
above was used. If the amount of metamizole that 
the patient obtained was known (dispensing prac-
tices), this was used for the calculation of the cumu-
lative and daily dose. When only the month and year 
of the start date was reported, we counted the rec-
orded month as a full month (30 days). In cases 
where several episodes of more than 28 days of met-
amizole intake with breaks between the episodes 
took place, only the longest episode was evaluated. 
The same laboratory values as in the case group 
were recorded, but at the nearest available date be-
fore the start date of metamizole as well as the new-
est values during the metamizole therapy. 
Statistical analysis 
Microsoft Office Excel (Version 2010, Redmond, 
Washington, USA) and GraphPad PRISM (Version 
6, La Jolla, California, USA) were used for descrip-
tive analyses. For variables with normally distrib-
uted numerical values, the arithmetic mean and 
standard deviation were calculated. For variables 
without normally distributed values, median and 
range were determined. In cases where the current 
body weight was missing, the last known value (last 
observation carried forward method) was used to 
calculate the BMI. Significance of differences be-
tween the cases and controls were assessed using 
univariate and multivariate conditional logistic re-
gression, the chi-square, Fisher exact test for small 
numbers, Mann-Whitney-U and Wilcoxon signed- 
rank tests as appropriate. Differences were consid-
ered as significant when p 0.05. Multivariate con-
ditional logistic regression models were constructed 
for postoperative and non-postoperative groups in-
dividually and for pooled data using variables that 
were significantly associated with the development 
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of leucopenia in the univariate analyses (p 0.05), 
using STATA 8.0 (College Station, USA). 
Results 
Fifty-seven cases of metamizole-associated leuco-
penia managed at the University Hospital Basel be-
tween April 2005 and August 2013 were included 
according to the predefined inclusion criteria. Of 
these, 32 were postoperative and 25 non-postopera-
tive. Of the 25 non-postoperative cases, 14 devel-
oped leucopenia prior to and 11 during hospitalisa-
tion. Sixty-four age-, sex- and ward-matched post-
operative controls and 75 sex-matched non-postop-
erative control patients from general practice set-
tings were identified. In total, 543 general practi-
tioners were approached, 19 of whom provided 93 
patients, from which 75 could be sex-matched to 
non-postoperative cases on a 1:3 basis. 
Patient and metamizole treatment characteris-
tics 
Table 1 summarises the patient characteristics. The 
median age of the non-postoperative controls was 
higher than that of the non-postoperative cases (79 
vs 51 years, p <0.001). In keeping with the older 
age, the number of diagnoses and total number of 
comedications per patient were also higher among 
those controls than in non-postoperative cases.
 
Table 1: Patient characteristics. 
 
Post-OP 
cases  
(n = 32) 
Post-OP 
controls 
(n = 64) 
p-value Non-post-
OP cases 
(n = 25) 
Non-post-
OP controls 
(n = 75) 
p-value 
Age in years at ADR diagnosis 
(cases) or at last intake (con-
trols); median (range) 
58 (16–82) 58 (16–82) 0.87a 51 (20–84) 79 (41–98) <0.001a 
Female; number (%) 17 (53) 34 (53) 1b 19 (76) 57 (76) 1b 
Body mass index in kg/m2; me-
dian (range) 
25 (20–45) 
n = 18 
26 (18–56) 
n = 56 
0.69a 21 (18–47) 
n = 11 
28 (16–40) 
n = 51 
0.18 a 
Co-morbidities 
 
     
Total number of diagnoses; 
median (range) 
5 (1–9) 2 (0–10) 0.004c 4 (1–9) 6 (2–11) 0.002c 
Number of chronic dis-
eases; median (range) 
2 (0–5) 2 (0–10) 0.27c 3 (0–6) 4 (1–9) <0.001c 
Number of patients with 
known allergy; number (%) 
16 (50) 12 (19) 0.004c 8 (32) 18 (24) 0.389c 
Previous leucopenic epi-
sodes; number (%)e 
3 (9) 0 (0) 0.03d 1 (4) 0 (0) 0.25d 
Underlying Hepatitis C in-
fection; number (%)f 
3 (9) 1 (2) 0.12c 2 (8) 0 (0) 0.061d 
 
Comedication (see also table 5)       
Total number of comedica-
tions; median (range)] 
9 (1–18) 5 (1–18) 0.001c 6 (1–18) 9 (0–19) 0.048c 
Patients concomitantly re-
ceiving non-chemothera-
peutic potentially myelo-
toxic comedication; num-
ber (%)g 
9 (28) 19 (30) 0.86c 6 (24) 33 (44) 0.09c 
Patients concomitantly re-
ceiving cytostatic agents; 
number (%)h 
3 (9) 2 (5) 0.23c 6 (24) 3 (4) 0.011c 
ADR = adverse drug reaction; post-OP = postoperative 
a Mann-Whitney U Test; b chi-square test; c univariate conditional logistic regression; d Fisher exact test; e pancytopenia n = 3, bicytopenia 
(anaemia and neutropenia) n = 1; f serology available for 7 post-OP-cases, 5 non-post-OP cases and 4 post-OP controls; g drugs with evidence 
level 1 for causing acute agranulocytosis according to Andersohn et al. 2007 [10]; h cytostatic agents included immunosuppressive-dose 
methotrexate, azathioprine and cancer chemotherapeutic drugs 
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In contrast, among postoperative cases, the total 
numbers of diagnoses and comedications were 
higher than among the age-, sex- and ward-matched 
controls. 
In the non-postoperative control group, metamizole 
was solely taken orally, whereas in the correspond-
ing case group, 20% received intravenous met-
amizole (table 2). As also shown in table 2, the mean 
daily metamizole dose did not differ significantly 
between non-postoperative cases and controls and 
was within the recommended range. The median 
treatment duration in the postoperative case group 
was 6 days and approximately two thirds of the 
cases took metamizole for 1 to 7 days. The median 
treatment duration in the non-postoperative case 
group was 13 days, with one third taking met-
amizole for 1 to 7 days. The non-postoperative con-
trols took metamizole per definition for at least 28 
days, one third for even longer than 1 year.
 
 
Table 2: Characteristics of metamizole therapy. 
 
Post-OP cases 
(n = 32) 
Post-OP controls 
(n = 64) 
Non-post-OP 
cases 
(n = 25) 
Non-post-OP 
controls 
(n = 75) 
Formulation     
Oral; number (%) 12 (38) 64 (100) 14 (56) 75 (100) 
Intravenous; number (%) 12 (38) 10 (16)a 5 (20) 0 (0) 
Unknown; number (%) 8 (25) 0 (0) 6 (24) 0 (0) 
Daily dose in g; mean (SD) 2.19 (1.22) 
n = 27 
3.36 (1.03) 
n = 40b 
1.99 (1.27) 
n = 17 
1.76 (0.82) 
Cumulative dose in g; mean (SD) 13.50 (0.5–94) 
n = 25 
na 21.6 (1–82.5) 
n=14 
316 (24–3109) 
Treatment duration in days; median (range) 6 (1–59) 
n= 29 
na 13 (1–365) 
n = 16 
187 (32–2192) 
Number (%) of patients treated for:     
1–7 days 18 (62) na 5 (31) n/a 
8–30 days 8 (28) na 8 (50) n/a 
31–60 days 3 (10) na 1 (6) 11 (15) 
61–120 days 0 (0) na 1 (6) 18 (24) 
121–180 days 0 (0) na 0 (0) 6 (8) 
180–365 days 0 (0) na 1 (6) 14 (19) 
>365 days 0 (0) na 0 (0) 26 (35) 
n/a = applicable; na = not available due to missing stop-date of metamizole intake; post-OP = postoperative; SD = standard deviation 
a intravenous administration followed by per oral administration; b during hospitalisation 
 
 
 
Characteristics of the leucopenia 
Figure 1 shows the leucocyte and neutrophil values 
for the case and control subgroups; all cases experi-
enced a distinct fall in leucocyte and neutrophil 
counts. Leucocyte counts measured during treat-
ment with metamizole were available for 72% of 
postoperative controls. Leucocyte counts before and 
during metamizole exposure were available for 53% 
and 52% of postoperative and non-postoperative 
controls, respectively. Among non-postoperative 
controls, 69% had a during-treatment leucocyte 
count result, all of which were above the lower limit 
of the reference range. No trend in haemoglobin and 
platelet counts was seen (fig. 2).
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Figure 1: Leucocyte and neutrophil counts before starting metamizole and at time of diagnosis of ADR (case groups A–D) or at 
last follow-up while taking metamizole (control groups E–H). Red lines indicate upper and lower reference values (10–3.5 × 
109/l for leucocytes and 6.7–1.3 × 109/l for neutrophils). ADR = adverse drug reaction; post-OP = postoperative 
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Figure 2: Haemoglobin and platelet counts before starting metamizole and at time of diagnosis of ADR (case group A–D) or at 
last follow-up while taking metamizole (control group EH). ADR adverse drug reaction; post-OP = postoperative 
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Table 3: Characteristics of the white blood cell disorders (all cases). 
 
All cases 
(n = 57) 
Naranjo Causality assessment; number (%)  
Definite 0 (0) 
Probable 20 (35) 
Possible 37 (65) 
Rechallenge information; number (%)  
Known positive rechallenge 3 (5) 
Known negative rechallenge 2 (4) 
Rechallenge with unknown outcome 1 (2) 
No known rechallenge 51 (89) 
Timing of ADR (n = 49)  
During therapy; number (%) 31 (63) 
1–7 days after last application; number (%) 14 (29) 
8–14 days after last application; number (%) 2 (4) 
>14 days after last application; number (%) 2 (4) 
Latency timea in days; median (range) 11 (1–368) 
ADR duration in days; median (range)  
With G-CSF (n = 16) 5.5 (1–20) 
Without G-CSF (n = 21) 5 (1–21) 
Unknown whether G-CSF given or not (n = 12) 5 (1–51) 
Time between ADR onset and nadir in days; median (range) 1 (0–36) 
Time between nadir and recovery in days; median (range) 4 (1–19) 
With G-CSF (n = 16) 3.5 (1–19) 
Without G-CSF (n = 21) 4 (1–13) 
Unknown whether G-CSF given or not (n = 12) 4 (1–16) 
Time between stopping metamizole and recovery in days (in cases where ADR occurred during 
metamizole therapy); median (range) 
 
With G-CSF (n = 9) 5 (1–29) 
Without G-CSF (n = 15) 4 (1–19) 
Unknown whether G-CSF given or not (n = 2) 6.5 (6–7) 
Degree of leucopenia (n = 56)  
Leucocytes 2–3.5 × 109/l; number (%) 18 (32) 
Leucocytes 1–2 × 109/l; number (%) 22 (39) 
Leucocytes <1 × 109/l: number (%) 16 (29) 
Degree of neutropenia (n = 55)  
Neutrophils 1–1.3 × 109/l; number (%) 10 (18) 
Neutrophils 0.5–1 × 109/l; number (%) 19 (35) 
Neutrophils <0.5 × 109/l; number (%) 26 (47) 
Outcome; number (%) 
 
Recovered 53 (93) 
Died 4 (7) 
ADR adverse drug reaction; G-CSF granulocyte colony stimulating factor 
a time between starting metamizole and the onset of the ADR 
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Table 3 shows the ADR characteristics among the 
cases. No cases fulfilled the criteria for a “definite” 
causality assessment according the Naranjo scale.  
The three cases that had a recurrence of the ADR on 
rechallenge would, however, have been classified as 
“certain” if the WHO–UMC Probability Scale had 
been applied [14]. 
The ADR appeared during the first week of treat-
ment in 40% and during the first 2 months in 93% 
of all cases. Nineteen patients (33%) were known to 
have been treated with granulocyte colony-stimulat-
ing factor (G-CSF). 
Four cases in the study had a fatal outcome. In two 
of them, metamizole was assessed as probably being 
causal and in the other two as possibly causal be-
cause concomitant methotrexate and azathioprine, 
respectively, were also suspected. All fatal cases 
were women (22, 71, 75 and 76 years old). One pa-
tient in the case group was recently re-exposed to 
metamizole with fatal outcome [15]. 
Comorbidities and their association with the 
ADR 
Figure 3 shows the course of the GFR at the start of 
metamizole therapy and at the start of the ADR in 
the case groups. In the cases, the GFR did not 
change significantly between these two time points. 
Among controls, an increase and a decrease in GFR 
were seen in the postoperative and non-postopera-
tive groups, respectively. These differences were, 
however, not clinically relevant. Three patients in 
the case group (one postoperative and two non-post-
operative cases) and one patient in the non-postop-
erative control group had pre-existing severe renal 
impairment (GFR <30 ml/min/1.73 m2) at the start 
of the metamizole therapy. However, the GFR in-
creased or remained clinically stable during the met-
amizole therapy in all cases (ranging from 16–61.2, 
24.4–34.0, 21.5–28.3 and 27.3–22.0 
ml/min/1.7 3m2, respectively). 
 
 
Figure 3: Estimated 
glomerular filtration 
rate (eGFR) at the 
start of metamizole 
therapy and at ADR 
start (case groups, 
left side), eGFR be-
fore the start of 
metamizole therapy 
and under met-
amizole therapy 
(control groups, 
right side), com-
pared with use of 
the Wilcoxon 
signed-rank test. 
ADR adverse drug 
reaction; post-OP = 
postoperative 
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Patients with a history of allergy were analysed in 
more detail (table 4). The number of known medi-
cation and non-medication allergies was signifi-
cantly higher in the postoperative case group com-
pared with the corresponding control group (p = 
0.003 and 0.026, respectively). The corresponding 
odds ratios (OR) for developing leucopenia if a 
medication or other type of allergy was present were 
5.44 (95% confidence interval [CI] 1.76– 6.8) and 
11.13 (95% CI 1.33–92.5), respectively. Specifi-
cally, the number of cases with beta-lactam allergies 
was significantly higher (p = 0.03). Among non-
postoperative cases and controls, there was a non-
statistically significant trend towards a higher prev-
alence of non-medication allergies among cases 
compared with controls (table 4). 
 
 
Table 4: Allergy history. 
 
Post-OP 
cases  
(n = 32) 
Post-OP 
controls 
(n = 64) 
p-valuea Non-
post-OP 
cases 
(n = 25) 
Non-
post-OP 
controls 
(n = 75) 
p-valuea 
Patients with known medication allergies; number 
(%) 
13 (41) 10 (16) 0.003a 6 (24) 15 (20) 0.67a 
Median number of trigger drugs in patients with 
medication allergies (range) 
3 (1–6) 1 (1–3)  1 (1–2) 1 (1–4)  
Trigger drugs; number (%)       
Beta-lactams:       
Total 9 (28) 6 (9) 0.028a 3 (12) 8 (11) 0.84a 
With skin reaction 5 2  2 4  
With anaphylactic reaction (dyspnoea) 1 –  1 –  
With unknown reaction 3 4  – 4  
Other antibiotics 4 1  – 3  
NSAID 4 4  1 5  
Opioids 1 –  1 2  
Others 5 3  2 6  
Patients with known non-medication allergy; number 
(%) 
7 (22) 3 (5) 0.026a 4 (16) 3 (4) 0.06a 
Allergic rhinitis 4 –  1 1  
Other allergies 5 3  3 1  
NSAID = nonsteroidal anti-inflammatory drug; post-OP = postoperative 
a Univariate conditional logistic regression 
 
 
Patients with a history of previous leucopenias were 
also analysed in more detail. One patient (a postop-
erative case) had a pre-existing bicytopenia (recur-
rent episodes of anaemia and neutropenia) of un-
known origin. The neutropenia re-emerged under 
metamizole and resolved again after stopping met-
amizole. In three cases (two postoperative and one 
non-postoperative), a pre-existing recurrent pancyt-
openia of uncertain origin had previously been di-
agnosed. In all of these cases, the leucocyte or neu-
trophil counts fell from a value within the normal 
range to a value below the lower limit of normal un-
der metamizole. Three other cases had a pre-exist-
ing haematological condition (one patient had hae-
mophilia B, one patient had an isolated factor VII 
deficiency and another chronic myelocytic leukae-
mia). 
Five patients in the case group (three postoperative 
and two non-postoperative cases) and one control 
patient were hepatitis C positive. Hepatitis C infec-
tion was not the reason for admission in any of these 
cases. When data from all cases and all controls to-
gether were analysed, there were significantly more 
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patients with underlying hepatitis C infection 
among cases than controls. The OR for developing 
leucopenia under metamizole among subjects with 
an underlying hepatitis C infection was 11.59 (95% 
CI 1.35–99.78, p = 0.026). After adjustment of the 
model for other variables that were significantly as-
sociated with leucopenia in the univariate analysis 
of the pooled data, namely presence of an allergy, 
concomitant use of cytostatic agents, number of co-
medications and number of chronic diseases, the OR 
was 35 (95% CI 2.99–409, p = 0.005). One patient 
with an underlying hepatitis C infection was co-in-
fected with hepatitis B and another with hepatitis B 
and human immunodeficiency virus (HIV). No 
other viral infectious diseases were known to be pre-
sent in either the case or the control groups. 
Comedications and their association with the 
adverse drug reaction 
The total number of patients concomitantly treated 
with potentially myelotoxic comedication was sim-
ilar in all groups (p = 0.86 postoperative cases vs 
controls and p = 0.09 non-postoperative cases vs 
controls; table 1). Potentially myelotoxic and cyto-
static comedications are listed in detail in table 5. In 
54% of all cases, comedication other than met-
amizole could potentially have also caused or con-
tributed to the ADR; however, these were taken into 
consideration when determining the Naranjo score. 
The number of patients treated with concomitant cy-
tostatic agents did not differ significantly between 
the postoperative case and control group (table 1). 
However, in the non-postoperative groups, a greater 
proportion of cases than controls received concom-
itant cytostatic agents (p = 0.011). 
Multiple conditional logistic regression analyses 
showed history of allergy and number of comedica-
tions to be independently associated with leucope-
nia in the setting of postoperative metamizole expo-
sure (OR 3.39, 95% CI 1.08–10.65; p = 0.037 and 
1.16, 95% CI 1.0–1.34; p = 0.045, respectively). In 
the comparison of non-postoperative cases with 
controls, independent variables associated with leu-
copenia were concomitant use of cytostatic drugs 
and number of chronic diseases (OR 15.84, 95% CI 
1.82–137.15; p = 0.012 and 0.24 95% CI 0.1–0.59, 
p = 0.002, respectively).
 
Table 5: Comedication known to be associated with agranulocytosis. 
 
Post-OP 
cases 
(n = 32) 
Post-OP 
controls 
(n = 64) 
Non-post-
OP cases 
(n = 25) 
Non-post-
OP con-
trols 
(n = 75) 
Total number of comedication 286 368 185 688 
Patients concomitantly receiving cytostatic agents; number (%)     
Methotrexate (low-dose) 2 (6) 3 (5) 3 (12) 2 (3) 
Azathioprine – – 2 (8) – 
Gemcitabine – – – 1 (1) 
Sorafenib – – 1 (4) – 
Ipilimumab 1 (3) – – – 
Cisplatin/5-fluorouracil – – 1 (4) – 
Patients concomitantly receiving non-chemotherapeutic poten-
tially myelotoxic comedicationa; number (%) 
    
Clopidogrel 1 (3) 2 (3) 1 (4) 3 (4) 
Diclofenac – – – 3 (4) 
Fluoxetine 1 (3) – – 3 (4) 
Ibuprofen 5 (16) 13 (20) 4 (16) 3 (4) 
Ramipril 2 (6) 4 (6) 2 (8) 15 (20) 
Spironolactone 1 (3) 1 (2) – 7 (9) 
Phenytoin 1 (3) 1 (2) – – 
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Table 5 (continued) 
Coprescribed drugs for which an association with the ADR could 
not be ruled out; number (%) 
    
Beta-lactam antibiotics     
Amoxicillin/Clavulanic acid 1 (3) 3 (5) 1 (4) 1 (1) 
Tazobactam/Piperacillin 8 (25)b 1 (2) 1 (4) – 
Flucloxacillin 2 (6)b – 1 (4) – 
Cephalosporin 1 (3) 2 (3) – – 
Not specified 1 (3) – 1 (4) – 
Other antibiotics     
Ciprofloxacin 4 (13) 3 (5) 1 (4) 1 (1) 
Moxifloxacin 1 (3) – – – 
Vancomycin 7 (22) – – – 
Tobramycin 1 (3) – – – 
Proton-pump inhibitor use     
Any proton-pump inhibitor 18 (56) 37 (58) 15 (60) 50 (67) 
Other drugs     
Quetiapine 1 (3) 2 (3) 1 (4) 6 (8) 
Acetylsalicylic acidc – 9 (14) 1 (4) 22 (29) 
Mesalazine – – 1 (4) – 
Rifampicin 2 (6) – – – 
Interferon – – 1 (4) – 
Gabapentin – 1 (2) 1 (4) 3 (4) 
Mirtazapine – 2 (3) 1 (4) 4 (5) 
Haloperidol 1 (3) – – – 
Caspofungin 1 (3) – – – 
Pregabalin – 2 (3) 1 (4) 7 (9) 
ADR = adverse drug reaction; post-OP = postoperative 
a Drugs with evidence level 1 for causing acute agranulocytosis (table 2) according Andersohn et al 2007 [10]; b In one case known to have 
been administered over several weeks; c Non-post-OP Case: analgesic dose, Non-post-OP controls: 20 cardiac doses, 1 analgesic dose, 1 
unknown dose 
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Discussion 
This retrospective study of metamizole-associated 
leucopenia identified a number of possible risk fac-
tors, namely a history of allergy, previous leucope-
nic episodes, infection with hepatitis C and concom-
itant use of cytostatic agents (including at immuno-
suppressive doses), which might allow targeted and 
safer metamizole use. This is of particular interest 
in view of the increasing use of metamizole in cen-
tral European countries such as Switzerland and 
Germany. 
Previous population-based studies of drug-induced 
agranulocytosis found a high incidence among older 
patients [16, 17]. Firm conclusions, however, can 
only be drawn if the exposure data of specific age 
groups are known, and the current study does not 
provide this. 
The opposing findings regarding the total number of 
diagnoses and concomitant medication among post-
operative and non-postoperative cases and controls 
probably reflects the inability to age-match in the 
non-postoperative groups. As the findings are in op-
position, we do not believe the total number of di-
agnoses or total number of comedications are risk 
factors for the development of metamizole-associ-
ated leucopenia; however, their role cannot be com-
pletely excluded. Clearly, a larger study is needed. 
The fact that the daily doses in the non-postopera-
tive case and control groups were similar and that 
postoperative controls were exposed to higher daily 
doses during hospitalisation compared with postop-
erative cases is evidence against a typical dose-de-
pendent toxic effect; rather it favours toxicity asso-
ciated with the presence of immunological or meta-
bolic susceptibility factors in affected patients. The 
median latency time of 11 days between the start of 
the metamizole therapy and the onset of the ADR 
(see table 3) lies within the 7 to 14 day latency time 
found in a previous analysis of pharmacovigilance 
data [5]. Similarly, the ADR appeared within the 
time-frame previously described in the pharma-
covigilance data study of 1417 reported cases of 
metamizole-induced white blood cell disorders [5] 
and in agreement with other previous studies [10, 
18]. These findings would support routine blood 
count monitoring during the first weeks of met-
amizole therapy, but this needs to be evaluated in a 
prospective, randomised fashion. Prior to this, the 
optimum time points and frequency of blood count 
monitoring should be determined. The benefits and 
costs of a screening programme for metamizole-in-
duced leucopenia would also have to be considered 
prospectively. 
The duration of the ADR was approximately 5 days, 
independent of the use of G-CSF, which is similar 
to the findings of Navarro-Martinez and colleagues 
[19]. This finding has to be interpreted in the light 
of the fact that the more severe cases tended to pref-
erentially receive G-CSF, despite the paucity of data 
supporting the benefit of G-CSF in this situation. 
No changes in GFR were seen under metamizole 
and there was no difference in GFR between the 
case and control groups (see fig. 3). Renal impair-
ment was, therefore, not found to be a risk factor for 
the development of metamizole-induced leucopenia 
in the present study. 
If the mechanism of toxicity has an immunological 
component, another possible risk factor could be a 
susceptibility to allergies, which our findings from 
postoperative patients support. The lack of associa-
tion between allergy history and the development of 
leucopenia in association with metamizole among 
non-postoperative cases compared with controls 
may be a chance finding or reflect the different data-
recording practices in hospitals and in general prac-
tice. The postoperative groups – all of which were 
inpatients in the same hospital – were subject to the 
same documentation process, so their data are more 
comparable. New concepts of immunological 
mechanisms, like the p-i-concept in which drugs or 
metabolites interact directly with T-cells, may help 
understanding of the mechanisms of the toxicity, 
which cannot easily be categorised into a classical 
known mechanism [20]. A genetic predisposition, 
which could not be examined in this study, may also 
be relevant: a genetic study of five patients who re-
covered from metamizole-induced agranulocytosis 
found an association with the presence or absence 
of specific human leucocyte antigen (HLA) types 
[21]. Similarly, other drugs known to cause agranu-
locytosis, such as thiourea antithyroid drugs, have 
recently been investigated in a genome-wide asso-
ciation study and patients possessing the HLA-
B*38:02:01 genotype were found to be at higher 
risk of developing this adverse drug reaction [22]. 
The role of genetic factors in the predisposition to 
developing leucopenia under metamizole requires 
further study. 
Of special interest were the cases with pre-existing 
haematological conditions, especially previous leu-
copenia. In two of the four patients with previous 
leucopenia, the likeliest cause was liver disease due 
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to HCV infection. In the other two patients, no rea-
son for the peripheral leucopenia could be found in 
a bone marrow study. Whether underlying haema-
tological conditions make patients more vulnerable 
to the haematotoxic effects of metamizole cannot be 
conclusively assessed here. However, these data 
suggest that pre-existing haematological conditions 
are a possible risk factor. 
Our observation regarding an increased prevalence 
of hepatitis C infection in patients who developed a 
metamizole-associated leucopenia compared with 
controls is in keeping with the increased risk of 
ADRs in the setting of viral infection seen with 
other drugs [23]. An increased risk for developing 
ADRs has been shown for HIV, hepatitis C, Ep-
stein-Barr virus, herpes simplex virus, human her-
pesvirus and cytomegalovirus infection [24–27]. 
Asymptomatic carriers of hepatitis B with normal 
liver function tests were found to have impaired 
clearance of metamizole via oxidative pathways 
compared with healthy controls, leading to in-
creased exposure to the 4-methylaminoantipyrine 
metabolite (carriers and controls all had slow the 
acetylator phenotype) [28]. In Western Europe, the 
prevalence of hepatitis C infection is estimated as 
2.4% [29]. Overall, our case group showed a preva-
lence of 9% and the control group a prevalence of 
1%. The exact mechanisms whereby viral infections 
cause an increased risk of ADR are not fully known, 
but could be any combination of a reduction in im-
mune tolerance, increased antigenicity or altered 
drug metabolism [23]. Furthermore, the chronic vi-
ral infection itself may be associated with altered 
blood counts, including leucopenia [30], and hepa-
titis C virus has been found to be present in the bone 
marrow of some infected patients [31]. It is likely 
that bone-marrow toxic agents and hepatitis C virus 
are co-risk factors for developing leucopenia; how-
ever, this requires further study. 
Regarding the co-administration of other bone-mar-
row toxic drugs, it is not always possible to separate 
out the impact the different drugs have on the ADR. 
This led to 54% of the cases receiving comedica-
tions that may or may not have contributed to the 
ADR. However, the administration of non-chemo-
therapeutic, potentially myelotoxic comedication, 
as given by Andersohn and colleagues, was not dif-
ferent between both types of cases and controls (see 
table 1). The use of beta-lactam antibiotics, particu-
larly at high doses and for a long duration, is known 
to be associated with the development of agranulo-
cytosis [32]. Concomitant use of cytostatic agents 
was more common among cases than their respec-
tive controls. Among non-postoperative patients 
this difference was statistically significant, indicat-
ing that the concomitant use of cytostatic agents 
might be a risk factor for the development of a white 
blood cell disorder under metamizole therapy. In the 
pharmacovigilance data study, coadministration of 
methotrexate was identified as a risk factor for a fa-
tal outcome [5]. In this study, two fatalities involv-
ing concomitant immunosuppressive-dose metho-
trexate and azathioprine, respectively, occurred. 
Retrospective studies are associated with a number 
of limitations. The problem of missing data is one 
important aspect and may have led to the inclusion 
of control patients who might have gone on to de-
velop a white blood cell disorder under metamizole, 
especially in the postoperative control group. Fur-
thermore, the limited number of study subjects, due 
to the rarity of the ADR, as well as the limited num-
ber of patients who take metamizole on a long-term 
basis reduces study power and precluded optimal 
matching. It is also possible that some cases and 
data were missed because of varying documentation 
policies. The inclusion of possible rather than only 
probable or confirmed cases according to the Na-
ranjo scoring system may have led to the inclusion 
of some cases where metamizole was not the likeli-
est cause of the white blood cell disorder. Lastly, the 
true prevalence of hepatitis C was not known, as 
hepatitis C testing is not routinely performed in ei-
ther the in-patient or general practice setting. Large-
scale, prospective studies are needed in order to re-
solve these limitations. 
Conclusion 
A history of allergy, previous leucopenic episodes, 
infection with hepatitis C and concomitant use of 
cytostatic agents (including at immunosuppressive 
doses), but not impaired renal function, might be 
risk factors for metamizole-induced leucopenia and 
require further study. 
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